KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Palvella Therapeutics (PVLA) Other Non Operating Income: 2014-2024

Historic Other Non Operating Income for Palvella Therapeutics (PVLA) over the last 11 years, with Dec 2024 value amounting to $1.7 million.

  • Palvella Therapeutics' Other Non Operating Income rose 293.40% to $1.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $771,000, marking a year-over-year increase of 8.29%. This contributed to the annual value of $1.1 million for FY2024, which is 54.49% up from last year.
  • Palvella Therapeutics' Other Non Operating Income amounted to $1.7 million in Q4 2024, which was up 393.66% from -$568,000 recorded in Q3 2024.
  • In the past 5 years, Palvella Therapeutics' Other Non Operating Income registered a high of $1.7 million during Q4 2024, and its lowest value of -$1.8 million during Q4 2020.
  • For the 3-year period, Palvella Therapeutics' Other Non Operating Income averaged around $232,167, with its median value being $86,000 (2022).
  • Its Other Non Operating Income has fluctuated over the past 5 years, first plummeted by 2,334.55% in 2020, then skyrocketed by 1,573.33% in 2021.
  • Over the past 5 years, Palvella Therapeutics' Other Non Operating Income (Quarterly) stood at -$1.8 million in 2020, then soared by 120.62% to $378,000 in 2021, then plummeted by 185.98% to -$325,000 in 2022, then skyrocketed by 230.46% to $424,000 in 2023, then surged by 293.40% to $1.7 million in 2024.
  • Its Other Non Operating Income was $1.7 million in Q4 2024, compared to -$568,000 in Q3 2024 and -$271,000 in Q2 2024.